Henry Welgemoed

A passionate and innovative healthcare professional with two decades of successful leadership in medical affairs, strategic planning, and product lifecycle management within the pharmaceutical industry. Therapeutic expertise encompasses haematology-oncology, medical oncology, immuno-oncology, radiation oncology, cancer supportive care, haematopoietic stem cell transplantation, immunology, and infectious disease. Possesses a robust background in developing and implementing medical affairs strategies for mainstream and orphan medicines in collaboration with R&D and commercial teams. Demonstrates a strong command of regulatory environments across multiple regions, including the US, UK, EU, and Asia-Pacific, ensuring alignment and compliance with health authorities. Proven ability to drive medical tactics that enhance patient access to critical therapies, manage cross-functional international teams, and lead business development initiatives that capture novel opportunities in competitive markets. Fundamental experience in early-stage clinical development, health technology assessment, early access programme management, and real-world data generation. Highly skilled in fostering relationships with key opinion leaders, patient advocacy groups, and cooperative bodies, navigating high-stakes negotiations, and expertly guiding products through competitive landscapes. Holds a significant track record of influencing product life cycles, consistently resulting in enhanced product uptake and sustained revenue growth.

Primary medical qualification: MBChB